<p>Fortrea Holdings（纳斯达克股票代码：FTRE）在过去三个月内被 7 位分析师进行了分析，显示出从看涨到看跌的多样化观点。</p>
<p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师们提供了更深入的见解，设定了 12 个月的价格目标，显示出平均目标为 17.29 美元，最高预估为 25.00 美元，最低预估为 10.00 美元。当前平均价格目标超过了之前的 10.57 美元，增长了 63.58%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769112083_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769112083_0.png"/></p>
<h2>分析师评级调查：详尽研究</h2>
<p>通过对最近分析师行动的全面分析，清晰描绘了 Fortrea Holdings 在金融专家中的认知。以下总结了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上调</td>
<td>持有</td>
<td>$15.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$22.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>上调</td>
<td>超越大盘</td>
<td>$25.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>上调</td>
<td>中立</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>上调</td>
<td>等权重</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$21.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>上调</td>
<td>低于权重</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Fortrea Holdings 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供了全面的分析，给出定性评估，从 ‘超越大盘’ 到 ‘低于大盘’。这些评级反映了对 Fortrea Holdings 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供了对 Fortrea Holdings 未来价值的估计。检查当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
<p>将这些分析师评估与其他财务指标结合考虑，可以提供对 Fortrea Holdings 市场地位的全面理解。保持信息灵通，做出明智的决策，参考我们的评级表。</p>
<p>随时了解 Fortrea Holdings 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>关于 Fortrea Holdings</h2>
<p>Fortrea 是一家全球性的晚期合同研究组织，提供从第一阶段到第四阶段的临床试验管理、临床药理学和患者接入解决方案。该公司与新兴和大型生物制药、医疗设备和诊断公司合作，作为功能服务提供商、全方位服务提供商进行临床试验，并提供混合试验。2023 年，Fortrea 作为一家独立的上市公司成立，此前 Labcorp 将其临床开发业务剥离，该业务是通过 2015 年以 61 亿美元收购 Covance 而获得的。Fortrea 在 90 个国家拥有 19,000 名员工。</p>
<h3>Fortrea Holdings 的经济影响：分析</h3>
<p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
<p><strong>收入增长：</strong> 在过去的 3 个月中，Fortrea Holdings 表现积极，截至 2025 年 9 月 30 日，其收入增长率为 <strong>3.91%</strong>。这反映了公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> Fortrea Holdings 的净利润率超过行业标准，突显了公司的卓越财务表现。其净利润率为 <strong>-2.27%</strong>，公司有效管理成本，实现了强劲的盈利能力。</p>
<p><strong>股本回报率（ROE）：</strong> Fortrea Holdings 的 ROE 低于行业平均水平，表明在有效利用股本方面面临挑战。其 ROE 为 <strong>-2.72%</strong>，公司可能在为股东创造最佳回报方面面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> Fortrea Holdings 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。其 ROA 为 <strong>-0.57%</strong>，公司可能在实现最佳财务回报方面面临困难。</p>
<p><strong>债务管理：</strong> Fortrea Holdings 的债务与股本比率为 <strong>2.04</strong>，面临有效管理债务水平的挑战，表明潜在的财务压力。</p>
<h2>理解分析师评级的相关性</h2>
<p>分析师是银行和金融系统中的专业人士，通常针对特定股票或定义的行业进行报告。这些人研究公司的财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
<p>一些分析师会发布他们对增长预估、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

<p>Fortrea Holdings（纳斯达克代码：FTRE）在过去三个月内获得了 7 位分析师的褒贬不一的评级，12 个月的平均目标价为 17.29 美元，比之前的目标上涨了 63.58%。分析师们提高了他们的评级，其中 TD Cowen 和 Truist Securities 等公司的增幅尤为显著。尽管 Fortrea 的收入增长率为 3.91%，但其市值低于行业平均水平，并面临着 2.04 的高负债权益比以及负的股本和资产回报率等挑战。分析师的评级反映了他们对公司业绩和市场状况的评估</p>

<p>Fortrea Holdings (NASDAQ: FTRE) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Fortrea Holdings（纳斯达克股票代码：FTRE）在过去三个月内被 7 位分析师进行了分析，显示出从看涨到看跌的多样化观点。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的简要概览，展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $17.29, along with a high estimate of $25.00 and a low estimate of $10.00. Surpassing the previous average price target of $10.57, the current average has increased by 63.58%.</p>
<div class="lb-trans"><p>分析师们提供了更深入的见解，设定了 12 个月的价格目标，显示出平均目标为 17.29 美元，最高预估为 25.00 美元，最低预估为 10.00 美元。当前平均价格目标超过了之前的 10.57 美元，增长了 63.58%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769112083_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769112083_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析师评级调查：详尽研究</h2>
</div><p>A clear picture of Fortrea Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的全面分析，清晰描绘了 Fortrea Holdings 在金融专家中的认知。以下总结了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$15.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上调</td>
<td>持有</td>
<td>$15.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$22.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>上调</td>
<td>超越大盘</td>
<td>$25.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>上调</td>
<td>中立</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>上调</td>
<td>等权重</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$21.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>上调</td>
<td>低于权重</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fortrea Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortrea Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Fortrea Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Fortrea Holdings 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供了全面的分析，给出定性评估，从 ‘超越大盘’ 到 ‘低于大盘’。这些评级反映了对 Fortrea Holdings 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供了对 Fortrea Holdings 未来价值的估计。检查当前和之前的目标提供了分析师预期变化的见解。</li>
</ul>
</div><p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Fortrea Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与其他财务指标结合考虑，可以提供对 Fortrea Holdings 市场地位的全面理解。保持信息灵通，做出明智的决策，参考我们的评级表。</p>
</div><p>Stay up to date on Fortrea Holdings analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Fortrea Holdings 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>About Fortrea Holdings</h2>
<div class="lb-trans"><h2>关于 Fortrea Holdings</h2>
</div><p>Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.</p>
<div class="lb-trans"><p>Fortrea 是一家全球性的晚期合同研究组织，提供从第一阶段到第四阶段的临床试验管理、临床药理学和患者接入解决方案。该公司与新兴和大型生物制药、医疗设备和诊断公司合作，作为功能服务提供商、全方位服务提供商进行临床试验，并提供混合试验。2023 年，Fortrea 作为一家独立的上市公司成立，此前 Labcorp 将其临床开发业务剥离，该业务是通过 2015 年以 61 亿美元收购 Covance 而获得的。Fortrea 在 90 个国家拥有 19,000 名员工。</p>
</div><h3>Fortrea Holdings's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Fortrea Holdings 的经济影响：分析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值低于行业平均水平，表明其相对于同行较小。这可能由于多种因素，包括被认为的增长潜力或运营规模。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3M period, Fortrea Holdings showcased positive performance, achieving a revenue growth rate of <strong>3.91%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 在过去的 3 个月中，Fortrea Holdings 表现积极，截至 2025 年 9 月 30 日，其收入增长率为 <strong>3.91%</strong>。这反映了公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司面临挑战，增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Fortrea Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.27%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Fortrea Holdings 的净利润率超过行业标准，突显了公司的卓越财务表现。其净利润率为 <strong>-2.27%</strong>，公司有效管理成本，实现了强劲的盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Fortrea Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.72%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Fortrea Holdings 的 ROE 低于行业平均水平，表明在有效利用股本方面面临挑战。其 ROE 为 <strong>-2.72%</strong>，公司可能在为股东创造最佳回报方面面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Fortrea Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.57%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Fortrea Holdings 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。其 ROA 为 <strong>-0.57%</strong>，公司可能在实现最佳财务回报方面面临困难。</p>
</div><p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.04</strong>, Fortrea Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Fortrea Holdings 的债务与股本比率为 <strong>2.04</strong>，面临有效管理债务水平的挑战，表明潜在的财务压力。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析师是银行和金融系统中的专业人士，通常针对特定股票或定义的行业进行报告。这些人研究公司的财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师会发布他们对增长预估、收益和收入等指标的预测，以提供额外的评级指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

数字之外：7 位分析师讨论 Fortrea Holdings 的股票